Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

14.87 -0.19 (-1.26%)
Streaming Delayed Price Updated: 11:56 AM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 215,988
Open 15.00
Bid (Size) 14.77 (200)
Ask (Size) 14.87 (200)
Prev. Close 15.06
Today's Range 14.39 - 15.04
52wk Range 5.680 - 16.74
Shares Outstanding 42,734,644
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+46.9%
+46.9%
1 Month
+16.7%
+16.7%
3 Month
+36.8%
+36.8%
6 Month
+73.7%
+73.7%
1 Year
+83.6%
+83.6%

More News

Read More
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Q3 2025 Earnings Beat Estimates and Announces Strategic Pipeline Refocus ↗
Via Chartmill
Topics Earnings
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations ↗
Via Benzinga
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cullinan (CGEM) Q2 R&D Jumps 68% ↗
Via The Motley Fool
News headline image
CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Reports Wider Q2 2025 Loss, Misses EPS Estimates Amid Rising R&D Costs ↗
Via Chartmill
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cullinan Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cullinan Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cullinan Therapeutics, Inc. - Common Stock trade on?
Cullinan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cullinan Therapeutics, Inc. - Common Stock?
The ticker symbol for Cullinan Therapeutics, Inc. - Common Stock is CGEM on the Nasdaq Stock Market
What is the current price of Cullinan Therapeutics, Inc. - Common Stock?
The current price of Cullinan Therapeutics, Inc. - Common Stock is 14.87
When was Cullinan Therapeutics, Inc. - Common Stock last traded?
The last trade of Cullinan Therapeutics, Inc. - Common Stock was at 04/20/26 11:56 AM ET
What is the market capitalization of Cullinan Therapeutics, Inc. - Common Stock?
The market capitalization of Cullinan Therapeutics, Inc. - Common Stock is 635.46M
How many shares of Cullinan Therapeutics, Inc. - Common Stock are outstanding?
Cullinan Therapeutics, Inc. - Common Stock has 635M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.